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To better understand the relationship between the surface polysaccharides of pulmonary pathogens and
components of the lung innate immune system, we employed selected serotypes of Klebsiella pneumoniae
expressing distinct capsular polysaccharides and/or O antigen in a murine model of K. pneumoniae infection.
In addition, we examined the effect of surfactant protein D (SP-D) on the cytokine response of human
monocyte-derived macrophages to these serotypes in vitro. Noncapsulated mannose-containing O3 serotypes
(K50/n and K55/n), which react efficiently with SP-D in vitro, triggered high levels of interleukin-1 (IL-1)
and IL-6 production. In vivo, they were more efficiently cleared from the lungs of mice but not from macro-
phage-depleted mice. They also were more efficiently internalized by alveolar macrophages in vivo. In contrast,
galactose-containing O1 serotypes (K2/n and K21a/n), which interact poorly with SP-D, exhibited significantly
lower cytokine production and less efficient pulmonary clearance and were ineffectively internalized by alveolar
macrophages. These findings are consistent with in vitro results showing that production of IL-1 and IL-6
mRNA and IL-6 protein by human macrophages exposed to mannose-bearing Klebsiella O serotypes is signif-
icantly increased by SP-D. Thus, survival of inhaled bacteria in the lung depends partially on the lipopoly-
saccharide structure of the bacteria and their interactions with innate immunity components. We speculate
that an imbalance of host SP-D and therefore cytokine levels may result in high susceptibility of the host to the
pathogen.
Host defense mechanisms of the innate, nonclonal, immune
system serve as the principal pathway for effective elimination
of pathogens from the lung (38). Impairment of innate immu-
nity is probably responsible for nosocomial infections caused
by pathogens such as Klebsiella pneumoniae, which is one of the
most frequent gram-negative bacterial pathogens isolated from
hospitalized patients with severe pneumonia (4, 17).
Alveolar macrophages (AM) and polymorphonuclear leuko-
cytes (PMNs) are potent cellular components of lung innate
immunity that mediate bacterial recognition and clearance
(35). The recruitment and activation of inflammatory cells at a
site of infection involve the orchestrated expression of leuko-
cyte and vascular adhesion molecules, as well as the establish-
ment of chemotactic gradients via the generation of chemo-
kines and cytokines (27). The attachment of the pathogen to
mannose receptors (MR) on phagocytic cells can trigger the
production of chemokines and cytokines (1, 43). The lung
collectins surfactant protein A (SP-A) and surfactant protein
D (SP-D) are also important components of pulmonary innate
immunity, which, like MR, contain C-type lectin domains
(6, 15). Both collectins can act as opsonins to enhance the
phagocytosis of bacteria by recognizing complementary carbo-
hydrates on bacterial surfaces and receptors on macrophages.
We have studied the interactions of K. pneumoniae with
SP-D, SP-A, and MR, three C-type lectins that are believed
to contribute to pulmonary innate immunity (29). Two types
of K. pneumoniae glycoconjugate structures are recognized
by lung C-type lectins. One of these is the capsular polysac-
charide (CPS), which is recognized by both SP-A and MR.
Binding of SP-A and MR to K. pneumoniae is serotype
dependent. Previous studies have shown that capsulated
K. pneumoniae strains that containing Man2/3Man or Rha2/
3Rha sequences in their CPS are directly recognized by the
macrophage MR or following opsonization with SP-A, which
results in attachment, ingestion, and killing of the bacteria by
the phagocytic cells (2, 18, 20). Capsulated Klebsiella strains
that lack such sequences in their CPS are not recognized by
either MR or SP-A. Significantly, the latter strains are isolated
from patients with pneumonia at a significantly higher fre-
quency than the capsular strains recognized by these C-type
lectins are isolated (28). The lipopolysaccharide (LPS) is an-
other cell wall glycoconjugate that can serve as a target for
recognition by collectins. SP-D, which selectively interacts with
* Corresponding author. Mailing address: Department of Human
Microbiology, Sackler Faculty of Medicine, Tel Aviv University, Tel
Aviv 69978, Israel. Phone: 972-3-6409871. Fax: 972-3-6406098. E-mail:
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the noncapsulated phase variant of K. pneumoniae, preferen-
tially binds to the conserved core region of LPS and enhances
phagocytosis by opsonic mechanisms (30).
The bacterial capsule is known to inhibit phagocytic clear-
ance. However, it has been shown that noncapsulated K. pneu-
moniae adheres better than the capsulated organisms to respi-
ratory epithelial cells (26). Thus, it is likely that most of the
bacteria colonizing the upper respiratory tract are in the non-
capsulated phase (29). Although there is currently no evidence
for an in vivo capsule switch in the lung, the phase variation
phenomenon with switching from capsulated variants to non-
capsulated variants occurs in vitro (28). In addition, most urine
isolates from patients with Klebsiella urinary tract infections
are noncapsulated, whereas the blood isolates are capsulated.
This strongly suggests that Klebsiella can undergo phase vari-
ation in vivo (26).
It has been suggested that SP-D provides early protection
against noncapsulated phase variants of Klebsiella because it
can recognize the conserved core oligosaccharide domain of
the LPS. However, it was recently found that SP-D can also
interact with specific O antigens and that the binding of SP-D
to serovars (serotypes) expressing LPS with a mannose-rich O
antigen is significantly greater than the binding to serovars
expressing a galactose-rich O antigen (37).
The present study was undertaken to determine whether
differences in O-antigen structure play a role in the pulmonary
response to Klebsiella. For this purpose, we employed a murine
model of lung infection and evaluated various O serotypes of
noncapsulated K. pneumoniae with respect to bacterial survival
of the bacteria and production of inflammatory cytokines in
vivo. We also examined the production of cytokines by mac-
rophages challenged with the serotypes in vitro. We found that
Klebsiella strains that efficiently bind and agglutinate SP-D via
their mannose-rich O antigens are less able to infect the lungs
of mice, yet they trigger higher levels of cytokine expression,
than strains expressing galactose-rich O antigens.
(This work was performed by Elena Kostina in partial ful-
fillment of the requirements for a Ph.D. degree from Sackler
Faculty of Medicine, Tel Aviv University.)
MATERIALS AND METHODS
Bacterial strains and growth conditions. Capsulated parent strains for capsu-
lar serotypes of K2, K21a, K50, and K55 were obtained as previously described
(30). Spontaneously noncapsulated phase variants of capsulated parent strains
K2/n, K21a/n, K50/n, and K55/n were selected from nonmucoid segments of
mucoid colonies as described elsewhere (26) to obtain noncapsulated derivatives
expressing O3 antigen (K50/n and K55/n) and O1 antigen (K2/n and K21a/n), as
determined previously (30). Noncapsulated K. pneumoniae strains KP79 (O1),
KP82 (O1), KP85 (O1), KP88 (O3), KP91 (O3), and KP94 (O3) were isolated at
the Department of Medical Microbiology and Virology, University of Kiel, Kiel,
Germany.
Bacteria were grown overnight on nutrient agar, harvested by scraping the
confluent growth, and resuspended at the desired density in phosphate-buffered
saline (PBS). CFU counting on agar plates showed that an optical density at 700
nm of 1 was equivalent to approximately 2  109 and 5  109 CFU/ml for
capsulated and noncapsulated phase variants, respectively. Stock suspensions
with 50-fold-higher cell densities were stored at 70°C with 20% (vol/vol) glyc-
erol. On the day of assay, bacteria were washed three times to remove the
glycerol, diluted to obtain the desired density, and incubated on ice before use
for various assays. The viability of the Klebsiella strains was checked by plating
serial 1:10 dilutions on MacConkey agar plates after freezing and thawing before
each experiment. We found that freezing and thawing did not affect the viability
of the bacteria (100% viability) (22).
Animals. Male BALB/c mice that were 6 to 8 weeks old were used throughout
this study. All mice were housed in the animal facility at Tel Aviv University.
Mice were treated according to the standards of the institutional animal care and
use committee of Tel Aviv University.
CP treatment of mice. BALB/c mice were inoculated intraperitoneally with
200 mg/kg of cyclophosphamide (CP). Animal weight and white blood cell counts
were monitored before the procedure and every 24 h until 4 days after CP
injection, when mice were inoculated with K. pneumoniae. The weight of mice
decreased from 20  1.2 g on the day of CP injection to 16  1.5 g 4 days after
CP injection. The white blood cell counts declined from 1.25  107 cells/ml for
nontreated mice to 1  104 cells/ml at 4 days after CP injection.
Pulmonary infection with K. pneumoniae. Each mouse was inoculated by in-
tranasal instillation of 20 l of a Klebsiella suspension (4  104 CFU of a
noncapsulated strain per mouse or 4  105 CFU of a capsulated strain per
mouse). Consistent with previously published work, differences in the host re-
sponse to the strains were assessed by determining the number of CFU at 72 h.
This time was needed for the bacteria to reach a critical mass that induced a
detectable response and for cytokines to be produced. A larger inoculum of the
capsulated strain was needed to achieve detectable levels of bacteria at this time.
Because the challenge was not lethal, dissemination was not assessed.
Alveolar macrophage depletion with clodronate (Cl2MDP) liposomes. Lipo-
some-encapsulated dichlormethylene diphosphonate (Cl2MDP) was prepared as
described previously (5). Cl2MDP was a gift from Roche Diagnostics GmbH,
Mannheim, Germany.
To deplete alveolar macrophages, 50 l of either clodronate- or PBS-treated
liposomes was inoculated intranasally 48 h before administration of bacteria as
described above. Clodronate reduced the number of alveolar macrophages from
4.04  105  2.31  105 cells to 1.7  104  2.7  104 cells.
Determination of viable bacterial counts in mouse lungs. Mice were anesthe-
tized by intraperitoneal injection of ketamine (100 mg/kg) and xylazine hydro-
chloride (6.25 mg/kg) (0.25 ml per mouse) and were sacrificed by cervical dislo-
cation 72 h after K. pneumoniae inoculation. Lungs were aseptically removed and
homogenized for up to 30 s in sterile glass tubes with 1 ml of sterile saline. The
lung homogenate was vigorously agitated with a Vortex mixer to disrupt bacterial
aggregates before the preparation was plated for CFU counting. The colony
counts before addition of SP-D and after addition of SP-D and vortexing were
the same. In previous studies this procedure was found to be effective for
breaking up large bacterial aggregates (30). Serial 1:10 dilutions were spread on
MacConkey agar plates (100 l/plate) and incubated for 18 to 20 h at 37°C, and
the numbers of viable bacterial CFU were determined. The data were expressed
as log10 CFU per lung per mouse (means  standard deviations).
Light microscopic assay of K. pneumoniae associated with alveolar macro-
phages. Mice were inoculated intranasally as described above with 4  106
CFU/mouse of either an O1 strain or an O3 strain. Three mice were inoculated
with each strain. Mice were anesthetized by intraperitoneal injection of ketamine
(100 mg/kg) and xylazine hydrochloride (6.25 mg/kg) (0.25 ml per mouse) 16 h
after the bacterial challenge. The trachea of each mouse was exposed and
intubated with a polyethylene catheter (21 gauge), and a bronchoalveolar lavage
(BAL) was performed with 1 ml of Dulbecco’s PBS without calcium and mag-
nesium (Beit-HaEmek, Rehovot, Israel). Approximately 0.5 to 0.7 ml of lavage
fluid was retrieved from each mouse. Next, the lavage fluid was centrifuged three
times at 350  g for 10 min to remove nonphagocytized bacteria from the AM.
BAL cells were resuspended in Dulbecco’s PBS and then centrifuged in a cyto-
centrifuge at 1,500 rpm for 10 min (Eppendorf 5416 centrifuge; Eppendorf,
Hamburg, Germany). Slides were stained by the Hemacolor method (17) and
were examined by light microscopy in order to determine the percentage of AM
associated with five or more bacteria. Three people counted at least 100 cells on
each slide.
Coating of Klebsiella by SP-D. Human SP-D dodecamers were prepared as
described previously (11), and bacteria were coated with SP-D as described
previously (22). The preparations contained low levels of endotoxin (50 pg/g
of protein), as measured by a chromogenic assay. Briefly, bacterial suspensions
(1  108 CFU/ml) were prepared in PBS supplemented with 20 mM CaCl2.
Equal volumes of a bacterial suspension and PBS containing 10 g/ml of SP-D
were incubated for 60 min at 37°C. The bacteria were then washed three times
by centrifugation at 12,000  g to remove unbound SP-D. The pellet was resus-
pended at the original density in PBS and maintained at 4°C before it was used
in assays. In previous studies we showed that the mannose-rich O3 strains
employed in the present study bind SP-D efficiently, while O1 strains bind SP-D
poorly in vitro (37).
Cytokine mRNA determination in mouse splenocytes. Spleens (three spleens
per group) were aseptically removed 72 h after infection with Klebsiella. The
spleen cells were prepared, counted, and used for RNA extraction with Tri
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Reagent (TR118; Molecular Research Center Inc., Cincinnati, OH). Reverse
transcription (RT) and PCR were performed using a reverse transcription system
kit (A3500; Promega Corporation, Madison, WI). DNA primers for the cyto-
kines of interest were purchased from Biotechnology General, Rehovot, Israel.
For interleukin-1 (IL-1) the upstream primer was 5	-TTGACGGACCCC
AAAAGATG-3	 and the downstream primer was 5	-AGAAGGTGCTCATGT
CCTCA-3	. For IL-6 the upstream primer was 5	-GTTCTCTGGGAAATCGTG
GA-3	 and the downstream primer was 5	-TGTACTCCAGGTAGCTATGG-3	.
For -actin the upstream primer was 5	-ATGGATGACGATATCGCT-3	 and
the downstream primer was 5	-ATGAGGTAGTCTGTCAGGT-3	.
Amplified cDNA was subjected to electrophoresis in a 1.5% agarose gel
containing 100 ng/ml ethidium bromide. Gels were viewed and photographed
under UV irradiation as described previously (20), and cytokine mRNA expres-
sion was measured by the TINA 2.1g program. The results were expressed as
ratios of the optical density of the cytokine to the optical density of -actin
(averages  standard errors) calculated from three separate experiments.
Preparation of lung homogenates for cytokine analysis. K. pneumoniae-inoc-
ulated mice were sacrificed after 72 h by intraperitoneal injection of ketamine
(100 mg/kg) and xylazine hydrochloride (6.25 mg/kg) in PBS (0.25 ml per mouse),
and whole lungs were harvested for assessment of the cytokine protein level.
Prior to lung removal, the pulmonary vasculature was perfused with PBS con-
taining 5 mM EDTA via the right ventricle. After removal, whole lungs were
homogenized in 3 ml of lysis buffer containing 0.5% Triton X-100, 150 mM NaCl,
15 mM Tris, 1 mM CaCl2, and 1 mM MgCl2 (pH 7.40) with a tissue homogenizer
(Biospec Products, Inc.). The homogenates were incubated on ice for 30 min and
then centrifuged at 1,400 g for 10 min. The supernatants were collected, passed
through a 0.45-m-pore-size filter (Gelman Sciences, Ann Arbor, MI), and then
stored at 20°C for assessment of cytokine levels (40).
Murine cytokine ELISA. The IL-6 in lung homogenates of normal and infected
mice was measured by an enzyme-linked immunosorbent assay (ELISA) (MM-
900 kit; Endogen, Massachusetts) performed according to the manufacturer’s
instructions. Triplicate samples of undiluted and diluted (1:3, 1:9) cell-free su-
pernatants were used. Plates were read at 450 to 650 nm with an ELISA reader,
and the results were expressed as the means  standard errors of the means for
two separate experiments (three mice per group).
Harvesting of human monocytes and MoDM. Human peripheral blood mono-
cytes were obtained from the buffy coat of normal blood bank donors. The
mononuclear fraction was separated on Ficoll-Hypaque (19), and adherent
monocyte monolayers (5  106 cells/ml in a tissue culture flask with a surface
area of 75 cm2) were reconstituted with RPMI-1640 supplemented with 100
g/ml of streptomycin, 100 U/ml of penicillin, 300 g/ml of glutamine, and 10%
newborn bovine serum. Cultured cells were further incubated for 10 to 14 days
in the presence of 100 U/ml of granulocyte-macrophage colony-stimulating fac-
tor (Behringwerke, Marburg, Germany) to obtain monocyte-derived macro-
phages (MoDM) and to promote MR expression (21).
Induction of cytokine mRNA expression by human monocytes and MoDM.
Monocytes and MoDM monolayers (107 cells per flask) were incubated for 30
min at 37°C with either 3 ml of medium containing 1 g/ml of LPS (Escherichia
coli O111:B4; Sigma-Aldrich, St. Louis, MO) or 3 ml of medium containing
108 CFU/ml of Klebsiella that was either not coated or precoated with SP-D (10
g/ml). The LPS was reconstituted in sterile PBS by vigorous vortexing. Total
RNA extraction was performed by the Tri Reagent method according the man-
ufacturer’s protocol (Molecular Research Center Inc., Cincinnati, OH).
RT-PCR analysis was performed using a two-step RT-PCR system (Promega
Corporation, Madison, WI) with 1 g of total RNA. The sense and antisense
PCR primers were used for amplification of human cytokine cDNA (BioTechnology
General Ltd., Rehovot, Israel). For IL-1 the upstream primer was 5	-ATGGCA
GAAGTACCTAAGCTCGC-3	 and the downstream primer was 5	-ACACAAATT
GCATGGTGAAGTCAGTT-3	. For IL-6 the upstream primer was 5	-ATGAAC
TCCTTCTCCACAAGCGC-3	 and the downstream primer was 5	-GAAGAGCCC
TCAGGCTGGACTG-3	. For -actin the upstream primer was 5	-ATGGATGAT
GATATCGCCGCG-3	 and the downstream primer was 5	-CTAGAAGCATTT
GCGGTGGACGATGGAGGGGCC-3	. PCR products were determined as de-
scribed above for mouse splenocytes. The results presented below are ratios of the
optical density of cytokine to the optical density of -actin (averages  standard
errors for three separate experiments).
Induction of IL-6 protein production by human monocytes and MoDM.
Monocytes and MoDM monolayers (107 cells per flask) were incubated with 3 ml
of medium containing 1 g/ml of LPS or with 3 ml of medium containing 108
CFU/ml of noncapsulated K. pneumoniae. After 30 min of incubation the cell
cultures were washed with warm Hanks balanced salt solution supplemented
with RPMI-1640 with 10% newborn bovine serum and incubated overnight at
37°C in the presence of 7% CO2. After incubation the supernatants were passed
through a 0.45-m filter and stored at 20°C.
An ELISA was used to measure IL-6 in the cell supernatants as described by
the manufacturer (CG50384; Endogen, Massachusetts). Triplicate samples of
undiluted and diluted (1:3, 1:9) cell-free supernatants were used. Plates were
read at 450 to 650 nm with an ELISA reader, and the results were expressed as
the means  standard errors of the means for three separate experiments.
Statistical analysis. All data obtained in vitro and in vivo were analyzed by
using a one-way analysis of variance (ANOVA) test and Student’s two-tailed t
test. Results were considered to be significantly different if the P value was0.05.
RESULTS
Survival of noncapsulated K. pneumoniae strains in mouse
lungs. Previous studies have shown that although SP-D binds
to the conserved region of all LPS serotypes (core region), the
affinity of the binding is considerably greater to serotype O3
LPS, which contains dimannose sequences, than to serotype
O1 LPS, which lacks such sequences. Significantly, we demon-
strated that five- to sevenfold-higher concentrations of SP-D
were needed to aggregate the O1 strains than to aggregate the
O3 strains (37). In this study we asked whether differences in
SP-D binding determine the survival of Klebsiella in mouse
lungs. Mice were infected intranasally with noncapsulated O3-
and O1-bearing K. pneumoniae strains, and the lung bacterial
load was measured after 3 days. The number of bacteria that
reached the lung by the intranasal route was very small, and
there was an initial growth phase of the bacteria (48 to 72 h).
During this period it was not possible to measure the rate of
infection accurately. Tanabe et al. (39), who also used intra-
nasal infection with Klebsiella, found that the bacterial counts
peaked 72 h after infection. The infection in mice resolved in
6 to 7 days, and the number of CFU after 3 days reflected the
process that occurred shortly after bacterial challenge. The
average mean level of recovery of five different O1-bearing
strains from the lung was 143 CFU, whereas the level of re-
covery of five O3-bearing strains was 6.3 CFU, so there was at
least a 20-fold difference in survival (P  0.013) (Table 1).
Notably, we did not detect significant neutrophil infiltration
TABLE 1. Effect of LPS O-antigen type of noncapsulated
K. pneumoniae strains on survival in the lungs of micea
O antigen Strain Log10 CFU per mouse(mean  SD)
O1 K2/n 2.66  0.1b
K21a/n 3.6  0.1b
KP79 1.36  0.4
KP82 3.2  0.1b
KP85 3.16  0.3b
O3 K50/n 1.5  0.1b
K55/n 1.7  0.02b
KP91 0.8b
KP94 0.8  0.7b
KP88 0.8b
a Normal BALB/c mice were inoculated with 4  104 CFU/mouse of five
O1-antigen-bearing Klebsiella strains (K2/n, K21a/n, KP79, KP82, KP85) and
five O3-bearing Klebsiella strains (K50/n, K55/n, KP88, KP91, KP94). Mice were
sacrificed 72 h after bacterial inoculation, the lungs were homogenized, and the
CFU were counted. The results are the results of three different experiments
(four animals per group).
b Statistical differences (as determined by an ANOVA test) were found be-
tween O1 strains (K2/n, K21a/n, KP82, KP85) and each of the O3 strains (P 
0.013).
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3 days after infection, which is consistent with the marked
predominance of macrophages in lavage samples at this time.
In order to examine the possible effect of PMN on the
survival of the organisms in the lung in this mouse model of
lung infection, we used cyclophosphamide, which causes de-
pletion of PMN (14) but does not reduce the number of alve-
olar macrophages following infection (16). The viable CFU
counts for K. pneumoniae O1 serotypes in the lung tissue of
both CP-treated and nontreated mice were 1.5 to 2.5 orders of
magnitude higher than the counts for O3 serotypes, irrespec-
tive of the capsular genetic background of the strains (P 
0.024). There was no significant difference in the pulmonary
survival of K. pneumoniae between CP-treated mice and mice
that were not treated (Fig. 1).
Our previous studies indicated that macrophages recognize
dimannose and dirhamnose structures in the capsular polysac-
charides of Klebsiella via their MR (22). Thus, it is possible that
the MR is responsible for the difference between the O1 and
O3 serotypes due to removal of the capsulated variants that
could arise from the noncapsulated variants during the infec-
tious process. Therefore, we examined the fate of the capsu-
lated parent strains of the noncapsulated variants. Mice were
infected with strains that were recognized by the macrophage
MR (K21a, K50) and a strain that was not recognized by the
MR (K2). The results showed that the survival of the capsu-
lated K2 strain was markedly (P  0.001) greater than the
survival of both the capsulated parent strains (K21a and K50)
(63  0.3 CFU for K2 and 1.2  0.5 and 10  2 for K21a and
K50, respectively), suggesting that the survival of the capsu-
lated parent strains was correlated with their interaction with
macrophage MR and was different from the survival of their
noncapsulated variants.
To establish the in vivo role of macrophages and their in-
teractions with different K. pneumoniae serotypes in the erad-
ication of Klebsiella from the lungs, alveolar macrophages were
depleted by intranasal inoculation of clodronate (Cl2MDP)-
containing liposomes. We then determined whether AM de-
pletion altered lung bacterial clearance. Figure 2 shows that
there was a 1-order-of-magnitude increase in the amount of
O3-containing noncapsulated bacteria in the lungs of mac-
rophage-depleted mice (2.57  0.33 CFU/lung/mouse for clo-
dronate-containing liposome-treated mice versus 1.5  0.12
CFU/lung/mouse for PBS-containing liposome-treated mice
for the K50/n Klebsiella strain [P 
 0.001]; 2.38  0.33 CFU/
lung/mouse for clodronate-containing liposome-treated mice
versus 1.73  0.9 CFU/lung/mouse for PBS-containing lipo-
some-treated mice for the K55/n Klebsiella strain [P 
 0.04]).
In contrast, the O1 bacterial infectivity was not affected by
macrophage depletion.
Association of Klebsiella with AM in vivo. In order to exam-
ine the role of O antigens in the interaction of bacteria with
alveolar macrophages in vivo, mice were infected with either
O1 antigen- or O3 antigen-bearing noncapsulated Klebsiella
strains, and 16 h later BAL cells were harvested and monitored
for bacterial association. No attempt was made to distinguish
between attached and internalized organisms using our light
microscopic assay. The results of the counting of six BAL
samples for each O serotype showed that the percentage of
FIG. 1. Survival of noncapsulated K. pneumoniae strains in the
lungs of BALB/c mice (normal and immunosuppressed). Normal and
CP-treated BALB/c mice were inoculated with 4  104 CFU/mouse of
the K50/n, K55/n, K2/n, and K21a/n Klebsiella strains. Mice were sac-
rificed 72 h after bacterial inoculation, the lungs were homogenized,
and the CFU were counted. The controls consisted of mock infections
without bacteria. The results are expressed as means and standard
deviations calculated from three different experiments (five animals
per group). Statistical differences (as determined by an ANOVA test)
between the O1 and O3 serotypes were found for normal (P  0.024)
and CP-treated (P  0.02) mice.
FIG. 2. Survival of noncapsulated K. pneumoniae strains in the
lungs of alveolar macrophage-depleted BALB/c mice. To deplete al-
veolar macrophages, 50 l of either clodronate- or PBS-containing
liposomes was inoculated intranasally 48 h before bacterial adminis-
tration. Clodronate-containing liposome-treated mice and PBS-con-
taining liposome-treated BALB/c mice were inoculated with 4  104
CFU/mouse of the K50/n, K55/n, K2/n, and K21a/n Klebsiella strains.
Mice were sacrificed 72 h after bacterial inoculation, the lungs were
homogenized, and the CFU were counted. The controls consisted of
mock infections without bacteria. The results are expressed as means
and standards deviation calculated from two different experiments
(six animals per group). Statistical differences (as determined by an
ANOVA test) between the O1 and O3 serotypes were found for
PBS-containing liposome-treated mice (P  0.024). Also, statistical
differences (as determined by the Student t test) were found be-
tween clodronate-containing liposome-treated mice and PBS-con-
taining liposome-treated mice inoculated with the K50/n mannose-
bearing O3-antigen K. pneumoniae strain (P 
 0.001) and between
clodronate-containing liposome-treated mice and PBS-containing
liposome-treated mice inoculated with the K55/n mannose-bearing
O3-antigen K. pneumoniae strain (P 
 0.04). No differences were
found between clodronate-containing liposome-treated mice and PBS-
containing liposome-treated mice inoculated with O1-antigen K. pneu-
moniae strains.
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BAL cells that had attached O3-antigen-bearing bacteria was
significantly higher than the percentage of BAL cells that had
attached O1-antigen-bearing bacteria (45% 6.5% and 23.7%
 3.21%, respectively; P 
 0.000374). Following intranasal
infection in this mouse model, we found no histological evi-
dence for acute lung inflammation (results not shown), and
more than 95% of the cells in the BAL were macrophages.
Cytokine production by splenocytes and in the lungs of
K. pneumoniae-infected mice. In order to investigate whether
the cytokine response to bacterial challenge is dependent on
the O-antigen structure of the different K. pneumoniae strains,
we determined the levels of IL-6 and IL-1 mRNA expressed
by splenocytes and the levels of IL-6 protein in whole-lung
extracts. The production of IL-1 mRNA by mouse spleno-
cytes was significantly greater in mice infected with O3 sero-
types than in mice infected with O1 serotypes (the optical
density ratios were 0.25  0.05 and 0.2  0.025 for K2/n and
K21a/n, respectively, compared with 0.37  0.025 and 0.35 
0.05 for K50/n and K55/n, respectively; P  0.04) (Fig. 3). The
levels of IL-6 mRNA production by splenocytes following
K. pneumoniae infection were dependent on both the O sero-
type, and the capsular genetic background of the noncapsu-
lated derivatives. IL-6 mRNA expression was not detected in
splenocytes of mice infected by the K2 strain (O1), and small
amounts were found in the splenocytes of mice infected with
the O1 serotype K21a strain (optical density ratio, 0.16 0.05).
Infection with O3 strains resulted in significantly higher
mRNA expression than infection with O1 strains (optical den-
sity ratios, 0.22  0.02 and 0.28  0.01 for K50/n and K55/n,
respectively) (P  0.00023) (Fig. 3).
In order to evaluate the local responses to the various
K. pneumoniae strains, IL-6 production was measured in whole
lungs of Klebsiella-infected mice. The levels of IL-6 protein in
the lungs of mice were significantly higher for O3 serotypes
than for O1 serotypes (3.83  0.05 and 5.34  0.1 ng/ml for
K50/n and K55/n, respectively, compared with 2.38  0.05 and
1.85  0.2 ng/ml for K2/n and K21a/n, respectively) (P 
0.0012) (Fig. 4). The cytokine response in vivo was measured
72 h after infection. As indicated in Materials and Methods,
this time was needed for the bacteria to reach a critical mass
which induced a detectable response and for cytokines to be
produced. A similar time was reported by Tanabe and cowork-
ers to be optimal for measuring tumor necrosis factor alpha
FIG. 3. Production of IL-1 and IL-6 mRNA by splenocytes from
mice infected with noncapsulated K. pneumoniae strains with different
O-antigen structures: RT-PCR analysis of spleen cells (three spleens
per group) from normal BALB/c mice infected with 4  104 CFU/
mouse of noncapsulated Klebsiella strains. The results are expressed as
average ratios of the optical density (OD) of cytokine to the optical
density of -actin (averages and standard errors). The data represent
the results of three experiments, measured by the TINA computer
program. The statistical differences for IL-1 mRNA production (as
determined by an ANOVA test) between the O3-bearing strains are
significantly greater than those between the O1-bearing strains (P 
0.04), and the statistical differences for IL-6 mRNA production (as
determined by an ANOVA test) between the O3-bearing strains are
significantly greater than those between the O1-bearing strains (P 
0.00023).
FIG. 4. Production of IL-6 protein by lung tissue from mice in-
fected with noncapsulated K. pneumoniae strains with different O-
antigen structures as measured by a specific sandwich ELISA in the
lungs of BALB/c mice (lungs of two mice per group). The data rep-
resent the results of three separate experiments. The controls con-
sisted of mock infections without bacteria. The statistical differences
for IL-6 protein production (as determined by an ANOVA test) be-
tween the O3-bearing strains are significantly greater than the differ-
ences between the O1-bearing strains (P  0.0012).
FIG. 5. Expression of IL-1 mRNA by human MoDM triggered by
SP-D-coated noncapsulated K. pneumoniae. Noncapsulated K. pneu-
moniae strains (108 CFU/ml) were incubated with human macrophages
with and without precoating with human SP-D (10 g/ml). Cytokine
mRNA expression was analyzed by RT-PCR. The results are expressed
as the ratios of the optical density (OD) of cytokine to the optical
density of -actin (averages and standard errors of three experiments).
Statistical differences (as determined by Student’s two-tailed t test)
were found for IL-1 mRNA production by MoDM exposed to the
K50/n (P 
 0.00004) and K55/n (P 
 0.000025) O3-bearing K. pneu-
moniae strains with SP-D and for IL-1 mRNA production by MoDM
exposed to the K50/n and K55/n O3-bearing K. pneumoniae strains
without SP-D.
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production in the lungs of mice following intranasal infection
with K. pneumoniae (39).
Effect of SP-D and O antigens on cytokine mRNA expression
and protein production by human macrophages exposed to
noncapsulated K. pneumoniae strains. In addition to the in vivo
and in vitro studies with mouse macrophages, we examined
cytokine production in human MoDM. SP-D-coated O3 sero-
type strains triggered higher levels of IL-1 mRNA than non-
coated bacteria (the optical density ratios were 4.95 0.03 and
3  0.01 for macrophages exposed to noncoated strains K50/n
and K55/n, respectively, compared with 8.8  0.1 and 4.8 
0.08 for macrophages exposed to SP-D-coated strains K50/n
and K55/n, respectively; P  0.00004) (Fig. 5).
A similar pattern was observed for IL-6 mRNA expression
(the optical density ratios were 1.9  0.02 and 1.8  0.005 for
macrophages exposed to noncoated strains K50/n and K55/n,
respectively, compared with 2.6  0.05 and 2.7  0.01 for
macrophages exposed to SP-D-coated strains K50/n and
K55/n, respectively; P  0.00038) (Fig. 6). In contrast, the
expression of IL-1 mRNA by macrophages exposed to O1-
bearing bacteria coated with SP-D was not significantly differ-
ent from the expression by cells exposed to noncoated bacteria
(Fig. 5), while the expression of IL-6 mRNA was significantly
suppressed (Fig. 6). The production of IL-6 protein was also
significantly suppressed by O1 bacteria treated with SP-D. In
contrast, IL-6 product was significantly increased (P  0.0134)
by SP-D-treated O3 bacteria compared to the results obtained
when nontreated O3 bacteria were used (Fig. 7).
DISCUSSION
K. pneumoniae can undergo phase variation between capsu-
lated and noncapsulated phenotypes (26). It has been hypoth-
esized that noncapsulated organisms preferentially adhere to
epithelial cells and colonize the upper respiratory tract (36).
Thus, noncapsulated variants are likely to be the first organ-
isms to enter the lung. If the noncapsulated bacteria escape
efficient recognition, they can multiply in the lung and shift to
the capsulated phase.
Previous studies have shown that noncapsulated K. pneu-
moniae strains expressing LPS structures whose O antigen is
rich in mannose residues, such as O3, bind better to SP-D and
are more efficiently aggregated by SP-D than strains expressing
O antigens lacking these structures, such as the galactose-rich
O1 antigen (37). Furthermore, SP-D promotes the killing of
K. pneumoniae by macrophages in vitro (30). In previous stud-
ies we found that the mannose receptor of macrophages inter-
acts poorly with noncapsulated O1 or O3 strains compared to
the interaction with capsulated strains bearing dimannose
structures in their capsular polysaccharides, suggesting that the
mannose structures on O3 LPS are different from those on the
capsular polysaccharides (22, 29).
In view of these observations, we examined the correlation
between SP-D binding by various noncapsulated variants of
Klebsiella and their abilities to cause lung infection in a mouse
model. Significantly higher numbers of noncapsulated O1-
bearing strains K2/n and K21a/n, which were not recognized by
the SP-D, than of the noncapsulated K50/n and K55/n O3-
mannose-bearing strains were recovered from the lungs of
infected mice. These findings are also consistent with epide-
miological studies showing that serotypes lacking mannose se-
quences in their CPS and O1-bearing Klebsiella serotypes are
the most common serotypes found among clinical isolates from
pneumonia patients (10). A possible explanation for the sero-
type-dependent differences is the interaction of the bacteria
with SP-D, with the resulting effects on bacterial agglutination
and phagocytosis by alveolar macrophages (29). Recently, SP-D
was also found to inhibit growth of some gram-negative bacteria
by altering the permeability of the outer membrane (42).
The recognition and phagocytosis of bacteria by macro-
phages at the initial stage of infection and the rate of bacterial
FIG. 6. Expression of IL-6 mRNA by human MoDM triggered by
SP-D-coated noncapsulated K. pneumoniae. Noncapsulated K. pneu-
moniae strains (108 CFU/ml) were incubated with human macrophages
with and without precoating with human SP-D (10 g/ml). Cytokine
mRNA expression was analyzed by RT-PCR. The results are expressed
ratios of the optical density (OD) of cytokine to the optical density of
-actin (averages and standard errors of three experiments). Statistical
differences (as determined by Student’s two-tailed t test) were found
for IL-6 mRNA production by MoDM exposed to the K50/n O3-
bearing K. pneumoniae strain with and without SP-D (P 
 0.035) and
for IL-6 mRNA production by MoDM exposed to the K55/n O3-
bearing K. pneumoniae strain with and without SP-D (P 
 0.00038).
FIG. 7. IL-6 protein production by human MoDM triggered by SP-
D-coated noncapsulated K. pneumoniae. Noncapsulated K. pneumoniae
strains (108 CFU/ml) were incubated with human macrophages with and
without precoating with human SP-D (10 g/ml). Cytokine protein pro-
duction was measured by a specific sandwich ELISA. The results are
expressed as averages and standard errors of three separate experi-
ments. Statistical differences (as determined by Student’s two-tailed t
test) were found for IL-6 protein production by MoDM exposed to the
K50/n O3-bearing K. pneumoniae strain (P 
 0.0037) and for IL-6
protein production by MoDM exposed to the K55/n O3-bearing K.
pneumoniae strain (P 
 0.0134).
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proliferation are key elements in the overall survival of the
bacteria. Differential interaction and opsonization by SP-D of
O1 and O3 serotypes may affect their clearance by AM and
thus be partially responsible for the differences in infectivity.
This was tested by infection of AM-depleted mice and as-
sociation of bacteria with AM in BAL fluid of Klebsiella-
infected mice.
Eradication of O3 mannose-containing serotypes was atten-
uated in macrophage-depleted mice, while clearance of sero-
types lacking O1 mannose was not changed. Our proposed
explanation for this is that O1 serotypes are not efficiently
opsonized by SP-D and thus are ineffectively cleared by mac-
rophages. Accordingly, removal of macrophages did not affect
the infectivity of the O1 bacteria. By contrast, O3 serotypes are
efficiently opsonized by SP-D, which permits efficient internal-
ization by macrophages. Removal of macrophages thus im-
paired O3 clearance in the mice. It was also observed that the
association of O1-bearing K. pneumoniae with lung AM was
significantly less than the association of O3 bearing bacteria.
We therefore suggest that impaired clearance of the O1 sero-
types results in part from low opsonization by SP-D and re-
moval by alveolar macrophages.
In order to examine the effect of PMN on the survival of the
organisms in the lung in this mouse model of lung infection, we
used cyclophosphamide, which causes depletion of PMN (14).
It was found that PMN play a minor role in the eradication of
Klebsiella from the lungs. Cyclophosphamide treatment that
reduced PMN blood levels by 1,000-fold did not have a signif-
icant effect on the survival of either O1 or O3 bacteria in the
lungs (Fig. 1). In addition, only minute amounts of PMN
were found by histological examination and in BAL fluid of
infected mice.
Although other C-type lectins, such as SP-A and macro-
phage MR, could play a role in the eradication of noncapsu-
lated bacteria, their involvement seems less likely. First, SP-A
and macrophage MR recognize the same capsular serotypes,
and noncapsulated variants interact poorly with these C-type
lectins (22, 29). Second, when the K2 and K21a strains, which
have the same O1 antigen, are in the capsulated form, they
express different capsular polysaccharide structures, which in-
fluence their clearance from the lung. In particular, the K21a
strain capsule is recognized by macrophage MR and is opso-
nized by SP-A (29). In contrast, there is no significant differ-
ence in the lung clearance of the noncapsulated variants of
these strains, which have the same O antigen. Nevertheless,
contributions by MR and SP-A can be excluded only by using
appropriate knockout models.
Previous studies have shown that SP-D can efficiently inter-
act with mannose-containing glycoconjugates (23, 33). These
molecules include the mannose oligosaccharides of influenza
A virus hemagglutinin (12), commercial preparations of yeast
mannan (24), and the GpA glycoprotein of Pneumocystis cari-
nii (25). Significantly, all the repeating units of the O1 antigen
lack mannose but contain galactose (32), a sugar that reacts
very weakly with SP-D (37).
Regulation of cytokine production by inflammatory cells
(e.g., alveolar macrophages) is now considered a critical deter-
minant of the innate immune response to microorganisms
(3, 47). The kinetics and synthesis of pro- and anti-inflamma-
tory cytokine production have been evaluated previously with a
K. pneumoniae murine pneumonia model (44, 45). IL-1 and
IL-6 are typical examples of multifunctional cytokines involved
in the regulation of hematopoiesis and inflammation. IL-1
plays an important role in inflammatory processes and induces
a wide range of hematological and metabolic responses (8).
IL-1 can augment the capacity of mononuclear phagocytes to
produce other inflammatory mediators, such as prostaglandins,
and IL-6. A clinical study previously showed that there was
localized production of IL-1, IL-6, and tumor necrosis factor
alpha in infected lungs of patients with community-acquired
pneumonia (7). In this regard, we observed that noncapsulated
K. pneumoniae strains with O3 mannose-bearing antigen trig-
gered high levels of IL-1 and IL-6 mRNA expression in
splenocytes and resulted in high levels of IL-6 protein in the
lungs of infected mice, while serotypes with the O1 antigen
lacking mannose sequences did not.
In addition to the in vivo studies with mice we also examined
the ability of O1 and O3 bacteria to stimulate human mono-
nuclear phagocytes and the role of SP-D in this stimulation. In
vitro experiments indicated that coating O3 mannose-contain-
ing serotypes (K50/n and K55/n) with SP-D significantly aug-
mented the mRNA and protein IL-6 responses, as well as the
mRNA IL-1 responses in human MoDM. Production of IL-6,
but not production of IL-1, was significantly suppressed by
O1 SP-D-treated bacteria compared to the production in non-
treated bacteria. In the absence of SP-D there were small
differences between the strains with regard to IL-1 and IL-6
induction, suggesting that the linear mannose residues of the
repeating units of the O3 antigen do not influence interactions
with MR-bearing macrophages, as was also found in our pre-
vious study (22). The findings are consistent with the in vivo
results showing that IL-6 expression by alveolar macrophages
of mice decreased following infection with O1 bacteria but
increased following infection with O3 bacteria. At present, it is
difficult to explain the downregulation of IL-6 production in
human MoDM exposed to SP-D-coated O1-bearing bacteria
(K2/n and K21a/n). It is possible that small amounts of SP-D
presented to macrophages by O1 serotypes downregulate their
capacity to produce cytokines, which is consistent with the
suggestion that lung SP-D can block proinflammatory media-
tor production (9).
The correlation between the survival of Klebsiella in mouse
lungs and cytokine production by SP-D-treated bacteria is in-
teresting. SP-D-coated O3-bearing bacteria, which trigger en-
hanced IL-1 and IL-6 production, were also eradicated faster
from the lungs of infected mice. In contrast, noncapsulated O1
serotypes (K2/n and K21a/n), which are significantly more vir-
ulent in the murine pneumonia model, triggered the same or
lower IL-1 and IL-6 production in vitro when they were
coated with SP-D. We suggest that this phenomenon depends
on opsonization of noncapsulated O3 serotypes by SP-D,
which results in faster elimination of the bacteria by macro-
phages and enhanced proinflammatory cytokine production
during the rapid clearance of the inoculated bacteria from the
lung. This speculation was confirmed by the in vivo results
showing that the differences between the survival of O3-bear-
ing serotypes and the survival of O1-bearing serotypes disap-
peared following alveolar macrophage depletion in the murine
pneumonia model. Indeed, it was previously shown that defec-
tive immunological host responses, including decreased IL-1,
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IL-6, and IFN- production, underlie the progression of
K. pneumoniae pulmonary infection to systemic septicemia
(46). Moreover, administration of IL-1 has been shown to
enhance nonspecific resistance in animals to several gram-
positive and gram-negative bacteria and fungi (41).
Because SP-D has been shown to bind or acts as an opsonin
for many microorganisms, including E. coli, Salmonella enterica
serovar Paratyphi, K. pneumoniae, P. carinii, and influenza A
virus, it was of interest to identify its role in vivo (13, 23, 31,
34). In this study we found that lung clearance is enhanced for
bacteria that express O antigen recognized by SP-D in vitro.
The process of bacterial phagocytosis may trigger induction of
a cytokine response, which is designed to set the stage for the
induction of clonal immunity and to enhance the bacterial clear-
ance. Although specific receptors involved in SP-D-mediated bac-
terial uptake have not been defined, macrophages are known to
possess receptors that can engage collectin-ligand complexes, with
resulting effects on the expression of cytokines (9).
The results of this study support the idea that the viru-
lence of K. pneumoniae strains is strongly correlated with
their CPS and O-antigen structure and involves innate im-
mune components, such as macrophages, SP-D, and cyto-
kines. The presence in the lung of both capsulated and
noncapsulated K. pneumoniae requires mechanisms that can
successfully defend against both bacterial forms. Thus, we
suggest that alveolar macrophages and their MR function
primarily against capsulated Klebsiella, while SP-D and mac-
rophages are responsible for the elimination of noncapsu-
lated bacteria. We speculate that an imbalance of such host
defense mechanisms increases the susceptibility of the host
to this pathogen.
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